A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines

NCT03907878 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Spontaneous Urticaria

Interventions

BIOLOGICAL: Ligelizumab

Sponsor

Novartis Pharmaceuticals